1405 todd manning

  • View
    65

  • Download
    0

Embed Size (px)

Text of 1405 todd manning

  1. 1. ABBVIE: A NEW PLAYER IN ONCOLOGY Todd Manning General Manager, AbbVie Ltd
  2. 2. The AbbVie oncology products are all investigational in nature and are currently not licensed in any country. The ultimate licensing of these compounds is subject to regulatory review and approval. 2
  3. 3. AbbVie Oncology Vision We will accomplish this by: Leveraging our leading-edge platforms Working closely with academia, diagnostic companies and cooperative groups Bringing to market novel therapeutics with transformational increases in efficacy and safety Transform the Lives of People with Cancer It starts with science and continues with AbbVies commitment to research and development 3
  4. 4. Oncology is a new focus for AbbVie AbbVie has a rich oncology pipeline in more than 15 different tumour types AbbVies late phase pipeline includes treatments for both haematological malignancies and solid tumours 4 Phase 1 7 molecules Phase 2 1 molecule Phase 3 3 molecules PARP inhibitor (solid tumours) potential indications6 Phase 2/3 trials19 BCL-2 inhibitor (haem malignancies) potential indications6 Phase 2/3 trials7 EGFR ADC (glioblastoma) potential indications2 Phase 2/3 trials2 PI3K inhibitor (haem malignancies) potential indications6 Phase 2/3 trials10
  5. 5. 5 Global Trials in Solid Tumours Brain Metastases Breast NSCLC SCLC Colorectal Ovarian Gastric Glioblastoma In 2014 - ~1100 subjects enrolled in Phase 1-3 trials ~60 trials performed across multiple tumours Studies conducted in 44 countries AbbVies oncology clinical development is founded on deep scientific and clinical expertise Global Trials in Haem. Malignancies Acute Myelogenous Leukemia Chronic Lymphocytic Leukemia Multiple Myeloma Non-Hodgkins Lymphoma Current Trials in Ireland Squamous non-small cell lung cancer Glioblastoma
  6. 6. Manufacturing in Ireland: 2 of AbbVies 3 oncology compounds in phase 3 trials are manufactured in Ireland Each of the uniquely focused sites in Ireland manufactures portions of AbbVies top 20 products The company has 12 sites in total across the United States, Europe and Puerto Rico, as well as strategic partnerships with third-party manufacturers Of the 3 oncology compounds in phase 3 trials, 2 are manufactured in Ireland 6
  7. 7. In addition to organic development of new compounds, AbbVie is also investing heavily in the oncology pipeline 7
  8. 8. Summary AbbVie is new to oncology, and has a number of compounds in pre-clinical, early phase and late phase development Late phase trials include both solid tumours and haematological malignancies, and enrolled over 1100 patients in 2014 AbbVie is investing in acquisitions and licensing compounds, in addition to the discovery and development process 8